CSCO
58
-2
FRT
41
-2
HRB
59
2
BMY
55
-8
NAVI
52
-2
VMC
53
-4
MTB
65
-2
A
37
-2
EOG
56
-2
KEY
43
-3
VRSK
68
-12
SWK
50
-5
PEP
39
-9
MSFT
48
-9
EQR
54
3
OI
42
-3
TGNA
50
-6
ESS
62
-3
LRCX
37
-9
IPG
34
-9
CSCO
58
-2
FRT
41
-2
HRB
59
2
BMY
55
-8
NAVI
52
-2
VMC
53
-4
MTB
65
-2
A
37
-2
EOG
56
-2
KEY
43
-3
VRSK
68
-12
SWK
50
-5
PEP
39
-9
MSFT
48
-9
EQR
54
3
OI
42
-3
TGNA
50
-6
ESS
62
-3
LRCX
37
-9
IPG
34
-9
Financhill
Back

Allogene Therapeutics 10K Form

Sell
15

ALLO
Allogene Therapeutics

Last Price:
2.27
Seasonality Move:
6.59%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ALLO News And Ratings

See the #1 stock for the next 7 days that we like better than ALLO

ALLO Financial Statistics

Sales & Book Value

Annual Sales: $95K
Cash Flow: $-44.54M
Price / Cash Flow: 0
Annual Sales: $2.21
Price / Book: 1.03

Profitability

EPS (TTM): -1.56000
Net Income (TTM): $-283.43M
Gross Margin: --
Return on Equity: 0%
Return on Assets: 0%

Allogene Therapeutics Earnings Forecast

Key Allogene Therapeutics Financial Ratios

  • The Research & Development expenses have been 255,698.95% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • Per Share Earnings over the last 6 years have been positive in 3 years.

Allogene Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: ALLO
CUSIP: 019770
Website: allogene.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

ALLO Technical Analysis vs Fundamental Analysis

Sell
15
Allogene Therapeutics (ALLO) is a Sell

Is Allogene Therapeutics a Buy or a Sell?